Physician profile
Kyle L Casey
NPI 1356844518
$1,585.31
in general payments reported to CMS, 2019-2025
30 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $73.28 · 2023: $345 · 2024: $561 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.04 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $209.82 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $130.05 | 2024-2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $101.01 | 2023-2025 | Fotivda |
| Abbvie INC. | $99.30 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $98.72 | 2023-2024 | Opdivo, Opdualag |
| Eisai INC. | $90.29 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $72.27 | 2023-2025 | Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $71.40 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $67.02 | 2024 | Libtayo |
| Exelixis INC. | $63.59 | 2022-2025 | Cabometyx |
| Emd Serono, INC. | $53.42 | 2024-2025 | |
| Glaxosmithkline, LLC. | $49.53 | 2024-2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $49.29 | 2023-2024 | Keytruda |
| Adc Therapeutics America, INC. | $36.33 | 2023 | |
| Pfizer INC. | $36.20 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $33.33 | 2023 | |
| Puma Biotechnology, INC. | $32.00 | 2024-2025 | |
| Blueprint Medicines Corporation | $29.95 | 2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $27.75 | 2024 | Iclusig |
| Pharmaessentia USA Corporation | $26.13 | 2024 | Besremi |
| Tersera Therapeutics LLC | $24.72 | 2023 | Zoladex |
| Genmab U.S., INC. | $24.04 | 2025 | Epkinly |
| Incyte Corporation | $23.38 | 2024 | Jakafi |
| Celgene Corporation | $22.48 | 2024 | Pomalyst |
| Beigene USA, INC. | $22.30 | 2024 | Brukinsa |
| Astellas Pharma US INC | $19.49 | 2025 | Vyloy |
| Array Biopharma INC | $19.00 | 2024 | Lorbrena, Braftovi, Bosulif |
| Bayer Healthcare Pharmaceuticals INC. | $18.33 | 2023 | |
| Cti Biopharma Corp. | $18.07 | 2022 | |
| Rigel Pharmaceuticals, INC. | $16.10 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.